For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Janux Therapeutics Inc (NASDAQ: JANX) was $48.82 for the day, down -2.96% from the previous closing price of $50.31. In other words, the price has decreased by -$2.96 from its previous closing price. On the day, 1.21 million shares were traded. JANX stock price reached its highest trading level at $52.38 during the session, while it also had its lowest trading level at $48.4.
Ratios:
Our analysis of JANX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 38.80 and its Current Ratio is at 38.80. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on November 22, 2024, initiated with a Outperform rating and assigned the stock a target price of $79.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $69.
On September 06, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $70.Stifel initiated its Buy rating on September 06, 2024, with a $70 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 01 ’24 when Reardon Tighe bought 5,202 shares for $53.44 per share.
Lichter Jay bought 1,139 shares of JANX for $60,723 on Nov 01 ’24. On Nov 01 ’24, another insider, Avalon Ventures XI, L.P., who serves as the 10% Owner of the company, bought 56,440 shares for $53.66 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 2562171136 and an Enterprise Value of 1927460736. For the stock, the TTM Price-to-Sale (P/S) ratio is 212.42 while its Price-to-Book (P/B) ratio in mrq is 3.89. Its current Enterprise Value per Revenue stands at 147.709 whereas that against EBITDA is -22.978.
Stock Price History:
Over the past 52 weeks, JANX has reached a high of $65.60, while it has fallen to a 52-week low of $7.79. The 50-Day Moving Average of the stock is -2.45%, while the 200-Day Moving Average is calculated to be 10.70%.
Shares Statistics:
JANX traded an average of 614.17K shares per day over the past three months and 617390 shares per day over the past ten days. A total of 46.25M shares are outstanding, with a floating share count of 42.64M. Insiders hold about 18.75% of the company’s shares, while institutions hold 86.63% stake in the company. Shares short for JANX as of 1730332800 were 4310503 with a Short Ratio of 7.02, compared to 1727654400 on 3460448. Therefore, it implies a Short% of Shares Outstanding of 4310503 and a Short% of Float of 16.229999.
